Pacira Pharmaceuticals Stock News

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive

Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Now is a good time to take a closer look at these stocks.

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ClearBridge Small Cap Growth Strategy underperformed its index benchmark during Q1. Who were the leading detractors and contributors? Click here to find out.

Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.

TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX ), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL ® (bupivacaine liposome injectable suspension) and iovera° for the month of February 2022. EXPAREL net product sales were $41.7 million, compared with $35.6 million for February 2021. EXPAREL average daily sales for the month of February 2022 were 117 percent of February 2021. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. The number of EXPAREL selling days were 20 in both February 2022 and February 2021. Net product sales of iovera° were $0.9 million for the month of February 2022, compared with $0.7 million for February 2021. "Strong year-over-year sales growth continues to be driven by the institutionalization of EXPAREL-based blocks as a cornerstone of enhanced recovery protocols across multiple surgical procedures," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "We also remain pleased with the progress we are making enhancing the awareness of the value of ZILRETTA and iovera° to our customers as both complementary and standalone non-opioid solutions for managing patients along the osteoarthritis pain continuum.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Con